Approved indications: Jakafi is approved for adults with intermediate‑ or high‑risk myelofibrosis (primary myelofibrosis, post‑polycythemia vera myelofibrosis, or post‑essential thrombocythemia myelofibrosis); adults with polycythemia vera who have had an inadequate response to or cannot tolerate hydroxyurea; and adults and children 12 years and older with steroid‑refractory acute graft‑versus‑host disease or with chronic graft‑versus‑host disease after failure of one or two prior systemic therapies.

Off‑label uses: Clinicians may occasionally use oral ruxolitinib off label for severe hyper‑inflammatory conditions such as hemophagocytic lymphohistiocytosis/macrophage activation syndrome or for certain autoimmune and dermatologic diseases, but current evidence is limited to small trials and case reports, so these uses remain investigational and are generally reserved for specialist centers.

Efficacy in myelofibrosis and polycythemia vera:

• In myelofibrosis, roughly 40% of patients achieve at least a 35% reduction in spleen volume by about 6 months, with many experiencing marked improvement in symptoms such as abdominal discomfort, early satiety, bone pain, night sweats, and itching; benefits often persist as long as treatment is continued.
• In polycythemia vera after hydroxyurea, Jakafi improves control of hematocrit and other blood counts, reduces the need for phlebotomy, and shrinks enlarged spleens in a substantial minority of patients, with many responders maintaining control for years.

Efficacy in graft‑versus‑host disease:

• In steroid‑refractory acute GVHD, many patients show responses within the first month; in a large trial, about 60% had an overall response by day 28, which was clearly higher than with best available therapy.
• In chronic GVHD after one or two prior systemic treatments, about half of patients achieved a response by 24 weeks, with improved symptom scores and longer failure‑free survival compared with standard options.

Comparison with other therapies: Versus traditional drugs such as hydroxyurea for polycythemia vera or various immunosuppressants for GVHD, Jakafi generally provides greater and more durable reductions in spleen size and symptom burden, though at the cost of more predictable bone‑marrow suppression and class‑related safety concerns that require close monitoring.

How Jakafi is taken: Jakafi is supplied as oral tablets in strengths of 5, 10, 15, 20, and 25 mg; tablets are usually swallowed twice daily, with or without food, at about the same times each day, and can be prepared as a suspension for administration through a nasogastric tube if swallowing is not possible.

Typical starting doses by condition (adults, unless noted):

• Myelofibrosis: Starting dose is based on platelet count: 20 mg twice daily if platelets are >200 ×10⁹/L, 15 mg twice daily if 100–200 ×10⁹/L, and 5 mg twice daily if 50–<100 ×10⁹/L, with later titration according to blood counts and symptom response.
• Polycythemia vera: Usual starting dose is 10 mg twice daily in adults who have not responded to or cannot tolerate hydroxyurea, adjusted over time up to a maximum of 25 mg twice daily as tolerated.
• Acute GVHD (age ≥12 years): Start at 5 mg twice daily and consider increasing to 10 mg twice daily after at least 3 days if neutrophil and platelet counts have not fallen by 50% or more from baseline.
• Chronic GVHD (age ≥12 years): Recommended starting dose is 10 mg twice daily, with adjustments based on blood counts, organ function, and response.

Special dosing considerations:

• Doses are individualized and often changed during the first weeks based on complete blood counts, kidney and liver function, and side effects.
• Lower starting doses or avoidance are required in moderate to severe renal impairment, end‑stage renal disease not on dialysis, and hepatic impairment, and when strong CYP3A4 inhibitors or fluconazole are used.
• When stopping treatment for reasons other than very low blood counts, clinicians may taper the dose gradually (for example, reducing by 5 mg twice daily each week) to reduce the risk of worsening symptoms.

Missed doses and overdose:

• If a dose is missed, do not take an extra tablet; simply take the next scheduled dose at the usual time.
• Taking more than prescribed can cause pronounced drops in blood counts and other side effects; if an overdose is suspected, contact the prescriber, poison control, or emergency services immediately for supportive care.

Common side effects:

• Low blood counts (anemia, thrombocytopenia, neutropenia) are very common, especially early in treatment, and can cause fatigue, shortness of breath, easy bruising or bleeding, and more frequent infections; they often require dose adjustments and sometimes transfusions.
• Non‑blood side effects that occur in many patients include bruising, dizziness, headache, diarrhea, weight gain, swelling (edema), and increases in blood lipids.
• In patients treated for acute or chronic GVHD, infections and fluid retention are particularly frequent because these patients are already heavily immunosuppressed.

Serious or rare adverse effects needing urgent attention:

• Signs of severe infection such as high fever, chills, cough, difficulty breathing, painful or blistering skin rash (including shingles), or confusion, because Jakafi can increase the risk of serious bacterial, viral, and fungal infections and can reactivate infections like tuberculosis or herpes.
• Severe drops in blood counts with profound fatigue, pale skin, rapid heartbeat, unusual bruising, nosebleeds, bleeding gums, or tiny red or purple spots on the skin.
• Sudden chest pain, shortness of breath, one‑sided weakness, trouble speaking, or severe headache, which may signal heart attack, stroke, pulmonary embolism, or deep‑vein thrombosis.
• New or changing skin lesions, since non‑melanoma skin cancers and other malignancies have been seen with JAK‑inhibitor therapy.
• Neurologic changes such as clumsiness, vision changes, or personality changes that worsen over days to weeks, which could indicate a rare brain infection called PML.

Warnings and precautions:

• Pregnancy: Animal studies show potential harm to the fetus; Jakafi is generally avoided in pregnancy, and effective birth control is recommended for people who could become pregnant during treatment.
• Breastfeeding: Women are advised not to breastfeed while taking Jakafi and for at least 2 weeks after the last dose, because the drug and its metabolites pass into milk in animal studies.
• Age limits: For myelofibrosis and polycythemia vera it is approved only in adults; for acute and chronic GVHD it is approved in adults and children 12 years and older.
• Kidney and liver disease: Moderate to severe renal impairment, end‑stage renal disease not on dialysis, or hepatic impairment require lower starting doses or avoidance, with closer monitoring of blood counts and organ function.
• Cardiovascular disease, clotting risk, or prior cancers: Because another JAK inhibitor has been linked to major cardiovascular events, blood clots, and secondary cancers in high‑risk patients, clinicians weigh risks and benefits carefully and monitor patients with these risk factors closely.

Overall safety compared with other drugs: Jakafi does not typically cause classic chemotherapy side effects such as hair loss or severe nausea, but it produces dose‑dependent bone‑marrow suppression and infection risk, so it requires more intensive blood‑count monitoring than many older oral agents.

Reporting side effects and finding safety updates: Patients and caregivers can report suspected side effects to the FDA MedWatch program (online or by calling 1‑800‑FDA‑1088) or to the manufacturer’s support line; current safety information is kept up to date in the full prescribing information and on FDA drug‑safety webpages.

Important drug and supplement interactions:

• Strong CYP3A4 inhibitors and fluconazole: Medicines such as ketoconazole, certain HIV protease inhibitors, and high‑dose fluconazole increase ruxolitinib levels, so Jakafi doses usually need to be reduced or temporarily interrupted; use with fluconazole doses above 200 mg daily is generally avoided.
• Strong CYP3A4 inducers: Drugs like rifampin, some anticonvulsants (for example carbamazepine or phenytoin), and herbal products such as St. John’s wort can lower ruxolitinib levels and may reduce its effectiveness, so prescribers may avoid these or monitor more closely.
• Other myelosuppressive therapies: Combining Jakafi with chemotherapy, other JAK inhibitors, or drugs that strongly suppress the bone marrow can increase the risk of severe anemia, neutropenia, or thrombocytopenia.
• Food, alcohol, and OTC medicines: Jakafi can be taken with or without food and has no major known food interactions; alcohol should be used cautiously, especially in people with liver disease or a history of heavy drinking, and all over‑the‑counter medicines and supplements should be reviewed with the prescriber.

Conditions that require caution or may make use unsafe:

• Active serious infections (such as uncontrolled tuberculosis, hepatitis B, severe bacterial or fungal infections) should be treated and stabilized before starting Jakafi.
• Very low baseline blood counts, particularly platelets below about 50 ×10⁹/L, may preclude safe treatment until counts improve.
• Moderate to severe kidney or liver impairment, prior blood clots, significant cardiovascular disease, or a history of other cancers warrant individualized risk–benefit assessment and closer monitoring.

Monitoring needs:

• Complete blood counts every 2–4 weeks at the start of therapy and then as clinically indicated to guide dose adjustments and detect cytopenias early.
• Lipid testing about 8–12 weeks after starting and periodically thereafter, since cholesterol and triglycerides can rise.
• Periodic skin examinations for new or changing lesions, especially in patients with prior skin cancers or high sun exposure.
• Ongoing checks for signs of infection, blood clots, and cardiovascular events, with additional liver or kidney tests as needed based on individual risk.

Diagnostic and imaging procedures: Jakafi has no known direct interactions with common imaging contrast agents or routine diagnostic tests, but patients should tell all healthcare providers, including dentists and radiology staff, that they are taking it so that infection risk and bleeding risk can be considered in procedure planning.

Q: What conditions is Jakafi used to treat?
A: Jakafi is prescribed for adults with certain bone marrow cancers called myelofibrosis and polycythemia vera (after hydroxyurea has not worked or caused side effects), and for adults and children 12 years and older with steroid‑refractory acute or chronic graft‑versus‑host disease.

Q: How long does it take for Jakafi to start working?
A: Some people notice symptom relief, such as less abdominal discomfort or itching, within a few weeks, while spleen shrinkage and full benefit in myelofibrosis or polycythemia vera often take several months, and graft‑versus‑host disease responses are usually assessed over the first 1–3 months.

Q: Will I need regular blood tests while taking Jakafi?
A: Yes, your healthcare team will check complete blood counts every 2–4 weeks at first and then as needed, and may also monitor cholesterol levels, liver and kidney function, and signs of infection or clotting to adjust your dose safely.

Q: Can I stop Jakafi once I feel better?
A: You should not stop Jakafi suddenly on your own, because symptoms and blood counts can worsen again; any dose change or discontinuation should be planned with your prescriber, who may taper the dose gradually.

Q: Does Jakafi weaken my immune system?
A: Jakafi reduces certain immune and inflammatory signals and can increase the risk of infections, so your doctor may review your vaccination status, advise on infection‑prevention measures, and ask you to report fevers or signs of illness promptly.

Storage: Store Jakafi tablets at room temperature (68°F to 77°F), keep the bottle tightly closed in a dry place, protect from excess heat and moisture, and always keep the medicine out of sight and reach of children and pets.

Disposal: Do not flush unused or expired Jakafi down the toilet; use a medicine take‑back program if available, or follow instructions from your pharmacist or local waste authority, and if none are available, mix tablets with an unappealing substance (such as used coffee grounds), seal in a container or bag, and place in household trash after removing or obscuring personal information on the bottle label.